this newly discovered antibiotic appears to block production of bacterial lipoproteins - while sparing most of the normal flora in the human gut microbiome
the lipoprotein targeting part may turn out to be significant for treating borrelia - since unlike most bacteria - borrelia's outer membrane is made from lipoproteins - so its possible they might be very sensitive to this substance.
if so this could lead to highly targeted and effective therapies
this is not going to be any time soon unfortunately as its not yet through FDA approval
but it is at east good to see some work being done on novel antimicrobials that could potentially be of use to us in the TBD community in the future
summary
article said...
In a recent study published in the journal Nature, researchers in the United States of America designed and discovered lolamicin, a selective antibiotic that targets the lipoprotein transport system in Gram-negative bacteria. They found that lolamicin was effective against multidrug-resistant Gram-negative pathogens, showed efficacy in mouse infection models, spared the gut microbiome, and prevented secondary infections.
link to news article
https://tinyurl.com/2ydkdujo